Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Home
ETF
RLYB
RLYB
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
RLYB News
Investor Rights Law Firm Investigates Multiple Companies for Potential Violations
Mar 06 2026
PRnewswire
Rallybio and Candid Merge to Advance T-Cell Engager Therapies
Mar 02 2026
Benzinga
Halper Sadeh Investigates Rallybio Merger with Candid Therapeutics
Mar 02 2026
Businesswire
Rallybio Acquires Candid Therapeutics, Shares Surge 27%
Mar 02 2026
seekingalpha
Rallybio Reports Positive Phase 1 Trial Results
Feb 17 2026
Benzinga
Biotech Update: IFRX, ABCL, RLYB Stand Out as Significant Gainers After Hours
Nov 10 2025
NASDAQ.COM
Rallybio Announces Financial Results for Q3 2025 and Shares Business Developments
Nov 06 2025
Newsfilter
Post-Market Activity: Biotech and Medtech Stocks Surge on Increased Volume and Announcements
Oct 03 2025
NASDAQ.COM
Rallybio Finishes Dosing Initial Group in Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study for RLYB116
Sep 25 2025
Newsfilter
Rallybio to sell interest in REV102 to Recursion Pharmaceuticals for up to $25M
Jul 09 2025
Yahoo Finance
Why Is Microcap Rallybio Stock Trading Higher On Tuesday?
Jul 08 2025
Benzinga
Rallybio Stock (RLYB) Rockets 25% on a Recursion Pharmaceuticals Agreement
Jul 08 2025
TipRanks
Rallybio Sells Interest in REV102 Program to Recursion Pharmaceuticals
Jul 08 2025
Newsfilter
Recursion to buy Rallybio’s ownership in jointly developed bone disorder drug
Jul 08 2025
SeekingAlpha
Rallybio to Present at the 2025 Citizens JMP Life Sciences Conference
Apr 29 2025
Newsfilter
This General Motors Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
Apr 15 2025
Benzinga
Show More News
